ProKidney (NASDAQ:PROK – Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01), FiscalAI reports. The firm had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.10 million.
ProKidney Price Performance
PROK stock opened at $1.66 on Friday. ProKidney has a 1 year low of $0.54 and a 1 year high of $7.13. The company has a market cap of $501.19 million, a P/E ratio of -3.13 and a beta of 1.70. The firm has a 50-day moving average of $1.96 and a 200 day moving average of $2.19.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on the stock. Jefferies Financial Group raised shares of ProKidney to a “strong-buy” rating in a research note on Wednesday, March 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProKidney in a research note on Tuesday, April 21st. Finally, Wall Street Zen downgraded shares of ProKidney from a “sell” rating to a “strong sell” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $7.40.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the company. Millennium Management LLC bought a new position in shares of ProKidney in the 3rd quarter worth approximately $4,734,000. JPMorgan Chase & Co. raised its position in shares of ProKidney by 3,024.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,668,642 shares of the company’s stock worth $988,000 after acquiring an additional 1,615,243 shares in the last quarter. Geode Capital Management LLC raised its position in shares of ProKidney by 9.2% in the 4th quarter. Geode Capital Management LLC now owns 1,197,530 shares of the company’s stock worth $2,684,000 after acquiring an additional 100,748 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of ProKidney by 578.6% in the 4th quarter. Renaissance Technologies LLC now owns 895,705 shares of the company’s stock worth $2,006,000 after acquiring an additional 763,705 shares in the last quarter. Finally, Bank of America Corp DE raised its position in shares of ProKidney by 12.4% in the 2nd quarter. Bank of America Corp DE now owns 846,154 shares of the company’s stock worth $501,000 after acquiring an additional 93,322 shares in the last quarter. Institutional investors own 51.59% of the company’s stock.
About ProKidney
ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.
ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.
Featured Stories
- Five stocks we like better than ProKidney
- Japan’s Stealth Bull Market: How U.S. Investors Can Get Exposure
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.
